AR039162A1 - Formulaciones de venlafaxina de liberacion extendida - Google Patents

Formulaciones de venlafaxina de liberacion extendida

Info

Publication number
AR039162A1
AR039162A1 ARP030101070A ARP030101070A AR039162A1 AR 039162 A1 AR039162 A1 AR 039162A1 AR P030101070 A ARP030101070 A AR P030101070A AR P030101070 A ARP030101070 A AR P030101070A AR 039162 A1 AR039162 A1 AR 039162A1
Authority
AR
Argentina
Prior art keywords
venlafaxina
liberation
formulations
extended
venlafaxine hydrochloride
Prior art date
Application number
ARP030101070A
Other languages
English (en)
Inventor
Johannes Jan Platteeuw
Lana Inocencia Margallo
Ortega Arturo Siles
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR039162A1 publication Critical patent/AR039162A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende clorhidrato de venlafaxina y carboximetilcelulosa de sodio, en donde preferiblemente está en la forma de una tableta que contiene una cantidad farmacéuticamente efectiva de clorhidrato de venlafaxina, y a un método para tratar una enfermedad o condición tratable con venlafaxina, que comprende administrar a un paciente en necesidad de la misma, una cantidad efectiva de la composición farmacéutica. Reivindicación 3: La composición farmacéutica de acuerdo con la reivindicación 1, en donde dicho clorhidrato de venlafaxina es clorhidrato de (+)-venlafaxina o clorhidrato de (-)-venlafaxina.
ARP030101070A 2002-03-28 2003-03-27 Formulaciones de venlafaxina de liberacion extendida AR039162A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36773502P 2002-03-28 2002-03-28

Publications (1)

Publication Number Publication Date
AR039162A1 true AR039162A1 (es) 2005-02-09

Family

ID=28675391

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101070A AR039162A1 (es) 2002-03-28 2003-03-27 Formulaciones de venlafaxina de liberacion extendida

Country Status (4)

Country Link
US (1) US20030190351A1 (es)
AR (1) AR039162A1 (es)
AU (1) AU2003219117A1 (es)
WO (1) WO2003082261A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
CN100348105C (zh) * 2003-10-01 2007-11-14 巴斯福股份公司 杀真菌剂混合物
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
WO2012068076A2 (en) * 2010-11-15 2012-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations containing soluble drugs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2001A (en) * 1841-03-12 Sawmill
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
US4083741A (en) * 1975-12-15 1978-04-11 Hoffmann-La Roche, Inc. Novel dosage form
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US5112490A (en) * 1986-02-19 1992-05-12 Jon Turpen Sample filtration, separation and dispensing device
JPH0810193B2 (ja) * 1989-08-21 1996-01-31 富士写真フイルム株式会社 生化学分析方法における点着異常判定方法
PT1153603E (pt) * 1993-06-28 2007-01-31 Wyeth Corp Novos tratamentos utilizando derivados de fenetilamina
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5866007A (en) * 1994-05-19 1999-02-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method and apparatus for the collection, storage, and real time analysis of blood and other bodily fluids
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
US6220453B1 (en) * 1998-04-07 2001-04-24 Fuji Photo Film Co., Ltd. Blood filter unit
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
KR100875610B1 (ko) * 2001-02-12 2008-12-26 와이어쓰 Ｏ-데스메틸-벤라팍신의 신규한 석시네이트 염

Also Published As

Publication number Publication date
US20030190351A1 (en) 2003-10-09
WO2003082261A1 (en) 2003-10-09
AU2003219117A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
CA2632207C (en) Use of calcitonin for the treatment of ra
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal